BOSTON — With so many topnotch research proposals seeking funding but only limited grant money to go around, deciding which among the best of the best projects to support is no easy task. What if you have a number of equally commendable applications and you don’t know how to break the tie? Usually, a panel of experts will weigh the merits of the various projects and come to some consensus behind closed doors. But in an unconventional twist, the Brigham and Women’s Hospital (BWH) has opted to let the general public act as scientific judge and jury.
After six weeks of online voting and nearly 6,500 votes cast, the decision was in. Today, the Harvard-affiliated hospital announced that a project designed to explore how best to integrate genomic sequencing into routine medical care for healthy newborns had won the inaugural BRIght Futures Prize. The project’s leader, clinical geneticist Robert Green, and his team received a $100,000 research grant from the BWH’s Biomedical Research Institute (BRI).
“I’m not sure if there’s any other example where an academic institution has allowed the public to decide to whom they’ll give some of their hard-earned, hard-raised research money,” says Jacqueline Slavik, executive director of the BRI.
“Our goal was really to engage the Brigham community at large,” adds Lesley Solomon, director of strategy and innovation at the institute. “We want the world to know about the breadth and depth of the research that goes on here.”
It may sound akin to a popularity contest, but Slavik and Solomon are quick to point out that all three finalists for the prize had gone through a rigorous, behind-the-scenes, peer-reviewed vetting process before reaching the final stage. Review committees with expertise in personalized medicine and systems immunology—the two subject areas for which the BRI solicited proposals for the prize—winnowed the list of applicants down to a series of semifinalists. Each selected applicant made an in-person pitch to the BRI’s Research Oversight Committee, which ultimately chose the three proposals that were presented to the public. The three finalists then worked together with the hospital’s public affairs team to create a series of videos and brief nontechnical descriptions about the projects that were hosted on the voting site.
“It’s a new way of trying to decide who gets the money when you have equally meritorious projects,” says Slavik. “We could flip a coin,” she quips. Instead, by engaging the public, “we achieve several goals at once,” without sacrificing scientific rigor.
The people have spoken
Experts involved in peer-review and grant funding commend the effort at public involvement. “In determining which [proposals] will have the most scientific impact, this is not the way I would choose. However, if one was also interested in getting the public into research more, this is an interesting approach,” says Richard Nakamura, acting director of the Center for Scientific Review in Bethesda, Maryland, which oversees the peer review process for the majority of research grant applications submitted to the US National Institutes of Health (NIH). “This could have some larger ripple effects.”
Robert Plenge, a rheumatologist and geneticist at BWH, is already seeing those effects. For the prize, he proposed to study the molecular signature generated by people with rheumatoid arthritis in response to anti–interleukin-6 therapy. After being selected as a finalist, several small news outlets in his local town of Wellesley, Massachusetts, ran articles and broadcasts featuring his work. “Suddenly, I could talk to friends and neighbors who aren’t in science about what I do for a living,” Plenge says. “At the end of all this, even though I didn’t win the prize, I have actually benefited from the process.”
Other entrants had similar experiences. The prize “gave us an opportunity to share what we were doing on Facebook and other social media, and I was actually surprised by the responses I got,” says Green. One friend wrote that sequencing newborns sounded like something out of the movie Gattaca. A college roommate who is also a pediatrician expressed concern with some of the ethics of the project. “There was engagement at levels I hadn’t quite expected,” Green says, “and that was kind of fun.”
In addition to his prize-winning project, Green is also leading a $9.6 million clinical trial funded by the NIH called MedSeq designed to study the use of whole-genome sequencing in routine medical practice among adults. He hopes that the seed money provided by the BRIght Futures Prize will help him secure NIH funding for a similar study in infants. He even has a name for that proposed project. He calls it BabySeq.
A version of this article appears in the December 2012 issue of Nature Medicine.